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Phase III clinical trials and post-licensure surveillance have demonstrated the safety and 
efficacy of human papillomavirus (HPV) vaccines. The U.S. Advisory Committee on 
Immunization Practices recommends universal HPV vaccination at age 11-12, alongside tetanus-
diphtheria-acellular pertussis (Tdap) and meningococcal conjugate (MenACWY) vaccination.  
Despite this recommendation, adolescents initiate HPV vaccination less frequently than 
Tdap and MenACWY vaccination, due partially to concerns about HPV vaccine safety. Reports 
of complex regional pain syndrome (CRPS) following HPV vaccination in Japan may have 
exacerbated safety concerns regarding HPV vaccination. To date, however, no epidemiologic 
research has linked HPV vaccination to CRPS. We analyzed private U.S. insurance claims 
between 2006-2014 to assess 1) patterns of use of HPV vaccination compared to Tdap and 
MenACWY among adolescents; and 2) the hazard of CRPS following HPV vaccination 
compared to Tdap and MenACWY among girls.  
Among 1,691,223 adolescents, HPV vaccination occurred later than Tdap or MenACWY 
vaccination. Half of vaccinated adolescents received Tdap and MenACWY vaccination only; 
however, co-administration of all three vaccines increased with birth cohort. Rural adolescents 
were less likely than urban adolescents to receive each vaccination except in the Northeast, 
where they were more likely to receive HPV vaccination (incidence rate ratio: 1.09, 95% CI: 
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1.05, 1.13). Timely HPV vaccination was associated with female sex, urbanicity, Western 
residence, and later birth cohort. 
We identified 563 CRPS cases among 1,232,572 girls. CRPS hazard was not significantly 
elevated following recent HPV, Tdap, or MenACWY vaccination. Ever receiving Tdap and 
MenACWY vaccination were associated with CRPS in crude analysis, but were not associated 
after adjusting for trauma. Concomitant administration of HPV vaccine with other adolescent 
vaccines conferred no excess hazard of CRPS. Girls with lower limb injuries had the greatest 
CRPS hazard compared to girls without (HR: 12.4, 95% CI: 10.4, 14.7), and common pediatric 
illnesses (e.g. asthma, respiratory infections, allergies) were positively associated with CRPS. 
HPV vaccination remains suboptimal among U.S. adolescents. We observed no vaccine 
safety signals with respect to CRPS, supporting current adolescent vaccination 
recommendations. Health care providers should strongly recommend timely HPV vaccination 
with other recommended adolescent vaccines to provide optimal protection against HPV-
associated cancers.
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CHAPTER 1: SPECIFIC AIMS 
The World Health Organization (WHO) recommends human papillomavirus (HPV) 
vaccination due to its strong safety profile and efficacy against cervical precancerous lesions, 
based on clinical trials and post-licensure surveillance. In the United States (U.S.), prophylactic 
HPV vaccination is recommended universally to adolescents aged 11 or 12 as part of the Centers 
for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) 
adolescent vaccine platform. However, due in part to safety concerns among adolescents and 
their parents, HPV vaccine uptake lags behind that of other ACIP-recommended adolescent 
vaccines, including tetanus-diphtheria-acellular pertussis (Tdap) and meningococcal conjugate 
(MenACWY) vaccines.  
Despite evidence of HPV vaccine safety, over 50 cases of Japanese adolescents with 
complex regional pain syndrome (CRPS), a nervous system disorder causing pain in the limbs, 
were reported by the Japanese media to be caused by HPV vaccination. Subsequent media 
coverage led to public disapproval of HPV vaccination, and the Japanese government withdrew 
its recommendation for HPV vaccination in June 2013. Uptake of HPV vaccination among 
eligible adolescents in Japan has since fallen from 80% to <5%, despite the fact that no scientific 
evidence has demonstrated an association between HPV vaccination and CRPS incidence.   
To promote universal uptake of this highly-effective prophylactic vaccine, it is critical to 
ensure that the benefits of HPV vaccination outweigh the risks. To thoroughly assess HPV 
vaccination safety, a large sample is needed to detect a sufficient number of vaccinations and 
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subsequent outcomes for analysis. The current study uses data from MarketScan®, a large 
employer-sponsored insurance claims database. The specific aims of this study are to: 
1) Describe the patterns of use of HPV vaccination, compared to Tdap and MenACWY 
vaccination, among adolescents from age 11 in the United States  
a) Estimate the incidence proportions of HPV vaccination among boys and girls by 
demographic characteristics, compared to Tdap and MenACWY vaccination. 
b) Compare the characteristics of adolescents vaccinated against HPV, Tdap, and 
MenACWY. 
c) Describe the most common combinations of adolescent vaccinations received and the 
incidence rates of concomitant administration of HPV, Tdap, and MenACWY vaccines. 
d) Estimate correlates of timely HPV vaccination at the ACIP-recommended ages. 
2) Estimate the hazard of CRPS following HPV vaccination, compared to Tdap and 
MenACWY vaccination, among adolescent girls from age 11 in the United States 
a) Estimate the incidence rate of CRPS among adolescent girls. 
b) Estimate the relative hazard (HR) of CRPS following recent (≤30/90 days) HPV, Tdap, 
or MenACWY vaccination compared to non-recent (>30/90 days) or no vaccination. 
i) Hypothesis: CRPS hazard will not be significantly elevated in recently-vaccinated 
compared to adolescents who were vaccinated in the past or were unvaccinated.  
ii) We ascertain vaccination status based on CPT codes and estimate hazard ratios (HRs) 
for the incidence of CRPS within the 30 days or 90 days following vaccination 
comparing recent vaccination recipients compared to past recipients or non-recipients. 
We will conduct sensitivity analyses eliminating the time window to assess the hazard 
of CRPS following recent and non-recent vaccination.  
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c) Estimate the relative hazard (HR) of CRPS following recent concomitant receipt of 
adolescent vaccines compared to receipt of single vaccines or reduced combinations of 
vaccines. 
i) Hypothesis: CRPS hazard will not be significantly elevated in adolescents recently 
vaccinated with combinations of vaccines compared to single vaccines or reduced 
combinations of vaccines, and there will be no excess hazard associated with 
concomitant vaccination. 
d) Identify other health diagnoses that are positively associated with CRPS incidence based 
on claims made by girls during follow-up. 
The results of this research will provide details on HPV vaccination use and characteristics of 
vaccinees to aid in targeted vaccination promotion to adolescents and their caregivers. Further, 
these findings will contribute to the evidence base for HPV vaccine safety, allowing healthcare 
providers and parents to make informed, evidence-based decisions regarding HPV vaccination in 
adolescents.
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
Prophylactic human papillomavirus vaccines 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
globally, with over 80% of sexually active adults acquiring HPV at least once during their lives.1 
While most HPV infections resolve on their own within one year, high-risk HPV (hrHPV) types 
can persist for longer and can develop into invasive cervical carcinoma.2 Cervical cancer is the 
fourth most frequent cancer in women globally; in 2012, an estimated 530,000 new cases of 
cervical cancer occurred, with approximately half of cases resulting in death.3 
Nearly 100% of cervical cancer cases are caused by hrHPV types, and 70% of cases are 
caused by hrHPV types 16 and 18. Phase III clinical trials of the prophylactic quadrivalent 
(4vHPV) and bivalent (2vHPV) HPV vaccines, licensed in the United States by the Food and 
Drug Administration (FDA) in 2006 and 2009, respectively, demonstrated over 90% efficacy 
against cervical abnormalities associated with types 16 and 18. The 4vHPV vaccine further 
demonstrated 90% efficacy against infection with types 6 and 11, which cause approximately 
90% of cases of genital warts.4,5 Clinical trials and post-licensure monitoring have also 
demonstrated a favorable safety profile of both vaccines, with few or no severe adverse events 
(SAEs) reported.5,6 In light of these findings, many countries began integrating HPV vaccination 
into their national immunization strategies to reduce the burden of HPV infections among young 
men and women. By November 2016, 87 countries had included HPV vaccination in their 
national immunization programs, primarily in the Americas, Europe, and the Western Pacific.7 
Recent safety and immunogenicity research also supports the co-administration of HPV vaccines 
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with other recommended adolescent vaccines, such as tetanus-diphtheria-acellular pertussis 
(Tdap) and meningococcal conjugate (MenACWY) vaccines, to reduce the burden of clinic visits 
and improve vaccine uptake and completion of the multi-dose HPV vaccination series.8  
Varying levels of vaccine coverage among adolescents and young adults have been 
observed globally, with financial and logistical barriers preventing many individuals from 
accessing HPV vaccination. However, coverage rates have exceeded 90% in settings where 
political support and a strong vaccine delivery system are in place.9 The public health 
community continually strives to reduce barriers to HPV vaccine uptake, with the goal of 
vaccinating as many eligible individuals as possible to reduce the incidence of potentially life-
threatening cervical cancer. 
Patterns of use of HPV and other adolescent vaccines 
 The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on 
Immunization Practices (ACIP) recommended routine MenACWY and Tdap vaccination for 
adolescents beginning at age 11, in 2005 and 2006, respectively.10–12 Shortly after its FDA 
approval in 2006, ACIP recommended routine 4vHPV vaccination for girls at age 11 or 12; 
2vHPV was recommended for girls at age 11 or 12 following its FDA approval in 2009. On 
October 21, 2009, ACIP extended the routine 4vHPV vaccination recommendation to 11 and 12-
year old boys, marking the first date at which all 11- and 12-year-olds were eligible to receive 
HPV, Tdap, and MenACWY vaccination. ACIP further recommends that all three vaccines be 
administered concomitantly (i.e. in the same visit).13  
Since 2006, the CDC has administered the annual National Immunization Survey – Teen 
(NIS-Teen) to monitor uptake of adolescent vaccines among adolescents aged 13-17 in the 
United States.14 NIS-Teen has consistently demonstrated that HPV coverage rates, or the 
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proportion of adolescents surveyed who had initiated vaccination, are lower than the coverage 
rates of Tdap and MenACWY vaccination, despite a wealth of evidence for the safety and 
efficacy of HPV vaccines.15 Further, many adolescents do not complete the multi-dose HPV 
vaccination series and fail to achieve optimal protection against hrHPV infection.15 Research on 
HPV vaccination attitudes among adolescents, young adults, and parents of adolescents reveals a 
distinct distrust of HPV vaccination that is not observed with respect to Tdap and MenACWY 
vaccination.16–18 The newness of the HPV vaccine relative to Tdap and MenACWY has 
contributed to concerns that not enough is known about the vaccine’s long-term safety, and fear 
of SAEs has been a major barrier to uptake and completion of the multi-dose series.19–21  
Despite sub-optimal uptake, HPV vaccination rates have increased over time with 
increasing awareness of and recommendation for vaccination. If there are indeed SAEs 
associated with HPV vaccination, then increasingly more individuals will be at risk for them. 
Thus, it is critical to provide continued evidence for the safety of HPV vaccines using rigorous 
scientific methods, and to develop risk mitigation strategies in the event that a link between HPV 
vaccination and SAEs is established.  
Adverse events monitoring following HPV vaccination 
A wide variety of local and systemic SAEs have been reported to post-licensure 
surveillance systems following HPV vaccination, including autoimmune diseases like Guillain-
Barre syndrome and central nervous system demyelinating disorders. Many studies using 
surveillance data and healthcare utilization data have demonstrated that SAEs do not occur more 
frequently in individuals who receive HPV vaccination relative to those who do not.22–31 HPV 
vaccination has been associated with increased risk of syncope (fainting) and anaphylaxis 
following an injection. However, these events are either considered not serious or rare, 
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respectively, and the risks of these events are not considered to outweigh the benefits of 
vaccination.23,27,30,32,33 HPV vaccines are contraindicated in individuals with sensitivity to yeast 
(4vHPV) and latex (2vHPV), and vaccine providers are encouraged to monitor patients for 15 
minutes following vaccination to prevent injury due to syncope.34 The World Health 
Organization (WHO) Global Advisory Committee on Vaccine Safety declared that the HPV 
vaccines were safe based on post-licensure safety surveillance from the United States and 
Australia, as well as surveillance conducted by the vaccines’ manufacturers.35 
  To date there is no scientific evidence to support the withdrawal of HPV vaccination 
recommendations based on the vaccines’ safety profiles. However, case reports have potentially 
identified rare SAEs that have not been rigorously evaluated in epidemiological studies. 
Dedicated studies can evaluate the risks of these SAEs to contribute to the evidence base for 
HPV vaccine safety.   
Complex regional pain syndrome  
Complex regional pain syndrome (CRPS) is a disorder of the peripheral nervous system 
causing chronic pain and discomfort in the limbs. Typical manifestations of CRPS include 
sensation and pain responses disproportionate to a stimulus (i.e., hyperesthesia and allodynia), 
dystrophic skin changes (such as reddening and thickening of skin), and changes in sudomotor 
and vasomotor functions.36,37 CRPS Types I and II often occur following an injury to the affected 
limb, such as a fracture or sprain, and share common diagnostic criteria. However, CRPS Type I 
occurs in the absence of a demonstrable nerve injury, and its pathophysiological mechanism 
remains unknown. Only two published estimates of CRPS Type I incidence are found in the 
literature, ranging from 20.57 cases/100,000 person-years over 11 years in Olmstead County, 
Minnesota, USA, to 26.2/100,000 (95% CI: 23.0, 29.7) person-years over 10 years in The 
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Netherlands.38,39 Both estimates were derived from large health records databases, using billing 
codes to identify CRPS cases and validating cases against medical records or secondary provider 
review. While apparently rare, CRPS can lead to long-lasting pain, reduced motor function, 
disability, disruption in daily activities, and reduced quality of life. 
Differing CRPS diagnostic criteria complicate research  
A CRPS diagnosis is made by ruling out other diseases based on clinical signs and 
symptoms, and cannot be confirmed with any particular combination of laboratory tests. The 
International Association for the Study of Pain (IASP) developed diagnostic criteria in 1994, 
which were highly sensitive for detecting CRPS not had low specificity for ruling out other 
chronic pain disorders. IASP revised these criteria in 2007 to be more specific; the proposed 
revisions to the criteria required signs and symptoms to be present at the time of observation.40 
However, both sets of criteria were validated in adult patient populations, and no criteria 
currently exist to diagnose CRPS in strictly pediatric populations.40,41 Pediatric CRPS case 
reports demonstrate that the clinical manifestation of CRPS differs from that in adult cases, and 
the diagnostic criteria developed for adults might be inappropriate for diagnosing pediatric cases.  
In contrast to adult cases, pediatric CRPS manifests primarily in girls, is more likely to 
involve a lower limb, less often involves neurological dysfunction, and more often involves 
psychological distress.42,43 Pediatric CRPS case reports often describe patients as having a 
history of psychological trauma or unstable familial relationships or home environments.44–62 
CRPS is often treated with a combination of analgesics and/or nerve blockers, physical therapy 
in the affected limb(s), and psychotherapy.43,61–64 The prognosis for children is typically more 
favorable than for adults, with a lower proportion of children experiencing long-term disability 
or dysfunction. In some cases, CRPS symptoms in children have resolved on their own without 
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intervention.65 In a study of CRPS patient outcomes following intense physical therapy, 
secondary episodes of pain occurred in one-third of patients, usually within six months of 
resolution of the initial episode. However, pain subsided following reinstatement of the physical 
therapy program.62  
HPV vaccination and CRPS in Japan 
In March 2013, local press in Japan reported on 50 cases of adolescent girls suffering 
from CRPS after receiving HPV vaccination.66 The CRPS patients and their families created 
advocacy groups critical of the government and demanded compensation for their injuries, but 
were largely denied on the basis that the vaccine was not part of the National Immunization 
Programme (NIP). One month later, in April 2013, HPV vaccination was integrated into the NIP; 
however, following pressure from victims’ groups, the Ministry of Health, Labor, and Welfare 
(MHLW) rescinded its recommendation for HPV vaccination in June 2013. By that time, over 8 
million individuals were estimated to have received the vaccine in Japan.67 A subsequent case 
series documented 40 young women reporting to a Japanese hospital, having received 2vHPV or 
4vHPV vaccination prior to onset of symptoms.68 These cases were diagnosed according to the 
historical IASP criteria with lower specificity, and may have been over-diagnosed in some cases. 
The report also failed to account for the prior trauma history of suspected CRPS cases, 
neglecting an important etiological component of CRPS development.  
Despite the weak evidence for an association between HPV vaccination and CRPS, the 
patients and their families used social media to promulgate anti-vaccine sentiment. Due to the 
wide reach of social media channels, fear and suspicion of HPV vaccines has the potential to 
spread rapidly across countries and regions. Further, the readiness of the Japanese government to 
rescind the recommendation for HPV vaccination likely validated public misconceptions of HPV 
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vaccine safety, even though this action was not based on scientific evidence. To date, no 
epidemiological studies have been conducted to rigorously measure the association between 
vaccination and CRPS incidence. A 2015 review by the European Medicines Agency (EMA) of 
the evidence from clinical trials and post-licensure surveillance concluded that HPV vaccination 
was not associated with elevated risk of CRPS or postural orthostatic tachycardia syndrome 
(POTS), which was also observed in some of the Japanese cases.69,70 Despite the lack of 
evidence for an association with CRPS, HPV vaccine uptake in Japan fell from nearly 80% to 
less than 5% by the end of 2014.71 If other countries follow suit based solely on public opinion, 
this potentially life-saving vaccine might fail to reach the populations at greatest risk for HPV 
infection.  
Hypothesized pathways for vaccine-induced CRPS 
The most commonly-identified causes of CRPS include a history of trauma to the limb or 
surrounding areas, including fractures, sprains, and surgeries.42,43,45,47–50,64,70,72–75 A 
pathophysiological mechanism for vaccine-induced CRPS has not been identified, but several 
hypotheses have been proposed. One hypothesis is that the needle itself inflicts damage on 
nerves at or near the injection site and incites excessive pain in individuals with underlying 
autonomic dysfunction; another is that injection-induced pain can cause the patient to immobilize 
or hold the affected arm in an unusual position, contributing to loss of function and continued 
pain.76–78 Following the review by the EMA, the researchers noted that “preceding viral illness” 
has been associated with CRPS development, much like injuries.69 The immune inflammatory 
response following vaccination could be such a trigger in recipients of HPV or other commonly 
administered vaccines. Indeed, several case reports have described CRPS development in 
adolescents following influenza, hepatitis B, diphtheria-tetanus, and rubella vaccination.44,65,79,80  
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Gaps in the literature 
HPV vaccination relative to Tdap and MenACWY vaccination has been studied annually 
through NIS-Teen since 2006. However, NIS-Teen has not assessed the influence of residential 
factors on vaccination patterns, or patterns of vaccine co-administration. Urbanicity has been a 
strong predictor of adolescent vaccination, but differences in urbanicity by region have not been 
assessed in the literature. Identifying areas with sub-optimal vaccination can help develop 
targeted pro-vaccination policies to ensure high coverage of these important vaccines. Co-
administration is important to ensure receipt of all adolescent vaccines, and with the increased 
uptake of HPV vaccination over time we would expect to see concomitant increases in co-
administration. Further, if there is a mechanism for vaccine-induced CRPS related to the number 
or combination of vaccines administered, it is necessary to understand these co-administration 
patterns from an objective data source so they can be assessed as risk factors for SAEs. 
The decision by the Japanese government to withdraw the recommendation for HPV 
vaccination was premature given that little is known about its association with CRPS incidence. 
CRPS is a rare disease, and it is difficult to conduct research in large enough samples of cases 
that would yield generalizable study findings. The literature is comprised primarily of case 
reports or case series from health care facilities reporting on small numbers of CRPS patients. 44–
48,50–53,55,57–59,65,72,73,77,79–92  Very few reports exist of cases following vaccination, and none of 
these assess a causal relationship between vaccination and CRPS using epidemiological 
methods.44,65,77,79,80 Facility-based studies with long study periods have managed to reach sample 
sizes of several hundreds and over 1,000 in one case, but these studies were largely descriptive 
and did not assess vaccination as a potential causal risk factor for CRPS.93–95  
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Large healthcare databases are useful tools to assess the use and safety of vaccines in large, 
diverse populations.  
Healthcare utilization databases, including electronic medical records and insurance 
claims databases, are increasingly used to study real-world use of pharmaceuticals, including 
vaccines. In the United States, NIS-Teen has been the primary tool for assessing uptake of HPV, 
Tdap, and MenACWY vaccination, and the Vaccine Adverse Events Reporting System 
(VAERS) and administrative data from managed care organizations have estimated the risks of 
SAEs following vaccination. However, NIS-Teen relies on random digit dialing to identify study 
participants, which may result in selection bias. Errors in parental recall of their children’s 
vaccination histories or providers’ medical records may lead to misclassification of vaccination 
status. VAERS is a passive surveillance system that is subject to underreporting of SAEs. 
Insurance claims data reduce these ascertainment errors by providing comprehensive and 
objective data on receipt of medical services, including specific medical procedures and 
diagnoses. Additionally, none of the previously-used databases has provided a sample size large 
enough to detect rare outcomes such as CRPS. Using large healthcare utilization databases can 
increase the sample size of CRPS cases by searching a large number of providers, facilities, and 
geographic areas. This type of data has never before been used to assess CRPS risk factors.  
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CHAPTER 3: METHODS 
Data source 
 The MarketScan® Commercial Claims and Encounters database, owned and maintained 
by Truven Health Analytics™, contains insurance claims of over 170 million unique enrollees 
from US-based healthcare facilities since 1995.96 MarketScan provides a large, diverse, and 
representative sample of enrollees in employer-sponsored health insurance plans. The database 
provides unique enrollee ID numbers in lieu of names, and patient location information is 
restricted to broad geographic areas to protect patient confidentiality. The data are maintained on 
a secure server administered by the UNC Cecil G. Sheps Center for Health Services Research, 
which is password-protected and accessible only to persons authorized by Truven Health 
Analytics to access the data.  
 MarketScan provides insurance claims in a variety of tables, including insurance plan 
enrollment details, claims for inpatient and outpatient medical services, and claims for 
prescription medication fills. Medical services claims are coded using International Statistical 
Classification of Diseases, Ninth Revision (ICD-9) codes to reflect the relevant diagnoses at the 
time of the encounter; Current Procedural Terminology (CPT) codes to reflect the medical 
procedures administered at the time of the encounter; and National Drug Codes (NDC) to 
identify prescription medications that were filled and billed to the enrollee’s insurance plan. We 
used MarketScan insurance claims to describe the patterns of use of HPV, Tdap, and MenACWY 
vaccines, and to estimate the incidence of CRPS and the hazard ratio (HR) for CRPS comparing 
adolescents who recently received HPV vaccination to those who did not. We used CPT codes to 
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ascertain exposures to HPV, Tdap, and MenACWY vaccination, ICD-9 codes to identify CRPS 
cases, and CPT, ICD-9, and NDC codes to indicate other health history variables of interest for 
the analyses described herein. 
Study population 
 All MarketScan enrollees are beneficiaries of employer-sponsored insurance plans, and 
adolescents are typically the children or other dependents of the primary beneficiaries. All 
enrollees are residents of the 50 United States, the District of Columbia, and Puerto Rico.  
We created open cohorts of 11-year-old enrollees for each research aim, based on the 
ACIP recommendations for HPV, Tdap, and MenACWY vaccination in adolescents from 11 
years of age. Specific Aim 1 included boys and girls, while Specific Aim 2 included girls only. 
We followed adolescents from their 11th birthdays, the earliest opportunity to receive adolescent 
vaccination per ACIP recommendations, to maximize the probability of capturing vaccination 
initiation. Adolescents who received HPV, Tdap, or MenACWY vaccination prior to age 11 
were eliminated from the final study sample. Because date of birth is protected health 
information, we searched monthly insurance enrollment files to identify the month in which the 
adolescent’s age changed, and then set the date of birth to the last day of that month. Some 
enrollees have more than one period of continuous insurance plan enrollment due to temporary 
loss or change of insurance coverage. The observation period for these enrollees was restricted to 
the enrollment period during which they turned 11, to avoid under-ascertainment of vaccination 




Specific Aim 1: Patterns of use of HPV, Tdap, and MenACWY vaccines 
The study period began October 21, 2009 – when ACIP supported HPV vaccination for 
boys – marking the first opportunity for all eligible adolescents to receive all three recommended 
vaccines. We included girls and boys who 1) turned 11 years of age between 2009 and 2014; 2) 
had no prior history of adolescent vaccination; and 3) had at least one year of continuous 
insurance plan enrollment prior to the start of follow-up. 
We searched outpatient services claims for the first billed claim for 2vHPV (CPT code 
90650) or 4vHPV (CPT code 90649), Tdap (CPT code 90715, ICD-9 code 9939), or MenACWY 
(CPT code 90734). We excluded Tdap claims related to injuries or accidents (ICD-9 codes 
037.X, 87X-91X, V01-V02, all E codes) or receipt of antenatal care (ICD-9 codes V22.X-
V39.X), as these instances do not reflect routine Tdap vaccination. While HPV vaccination 
requires multiple doses and MenACWY vaccine requires a booster, limited follow-up times 
might prevent us from observing all recommended doses of these vaccines. Thus, we focused our 
analyses on initiation of these vaccines rather than completion of the series.  
We followed adolescents until the end of their enrollment period or December 31, 2014, 
the last date for which claims data were available. Outcomes of primary interest included uptake 
proportions for each vaccine, the prevalence of different vaccination combinations, incidence 
rates of vaccine co-administration over time, and timeliness of HPV vaccination. The time to 
vaccination for HPV, Tdap, and MenACWY was estimated as the difference between the 11th 
birthday and the date of the first vaccination. We used generalized estimating equations with a 
Poisson distribution and a robust variance estimator to estimate incidence rate ratios (IRR) and 
95% confidence intervals (CI) for correlates of vaccination, and incidence rates (IR) of vaccine 
co-administration over time. Descriptive statistics summarized service-related characteristics at 
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the time of vaccination, and receipt of multiple and co-administered vaccines. We plotted the 
cumulative incidence of receiving the first dose of HPV vaccine at age 11 or 12 (i.e. timely HPV 
vaccination). Incidence rates and cumulative incidence of vaccination were stratified by 
covariates of interest, including sex; region (Northeast, North Central, South, West); urbanicity, 
as defined by urban residence (metropolitan statistical area with population ≥50,000) or rural 
residence (micropolitan statistical area with population <50,000); and insurance plan type.  
As many as 18 states have offered at least one adolescent vaccine free of charge, 
regardless of income level, since 2006 (Alaska, Connecticut, Hawaii, Idaho, Massachusetts, 
Maine, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Oregon, Rhode 
Island, South Dakota, Vermont, Washington, Wisconsin, and Wyoming).97 Adolescents from 
these states may have received vaccines without filing insurance claims, and thus their 
vaccination status would not be ascertained from MarketScan data. We conducted a sensitivity 
analysis excluding these states to assess potential bias due to under-ascertainment of vaccination 
status.  
Specific Aim 2: Hazard of CRPS following recent HPV, Tdap, or MenACWY vaccination 
To test our Aim 2 hypothesis, we estimated that we would require a sample size of 
approximately 250,000 to achieve 80% power to identify a 100% increased hazard of CRPS in 
vaccinated adolescents (i.e. HR=2.0), assuming the lowest incidence rate reported in the 
literature (20.57 cases/100,000 person-years).  
The study period began June 29, 2006 – the date of the ACIP recommendation for HPV 
vaccination in girls – and ended December 31, 2014. We included girls who 1) turned 11 years 
of age between 2006 and 2014; 2) had no prior claims for adolescent vaccination or CRPS; and 
3) had at least one year of continuous insurance plan enrollment prior to the 11th birthday. We 
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observed girls from the 11th birthday until the date of a claim for a CRPS diagnosis, or 
censorship at disenrollment from their insurance plan or December 31, 2014. For girls with 
multiple continuous enrollment periods, we restricted observation to the enrollment period that 
included the 11th birthday. Because date of birth is protected health information, we searched 
monthly insurance enrollment files to identify the month in which the adolescent’s age changed, 
and then set the date of birth to the last day of that month.  
The primary exposures were receipt of 2vHPV(CPT code 90650) or 4vHPV (CPT code 
90649), Tdap (CPT code 90715, ICD-9 code 9939), or MenACWY (CPT code 90734) 
vaccination, or concomitant Tdap+MenACWY. Secondary exposures included co-administration 
of HPV vaccine with one or more of Tdap, MenACWY, or influenza (CPT codes 4037F, 90658-
90688, 90724, 90737) vaccines, and the co-administration of HPV vaccine with 
Tdap+MenACWY. By identifying multiple exposure patterns we were able to assess 1) the 
individual associations of each vaccine with CRPS, and 2) any additional influence of co-
administration or specific co-administered combinations on the association between adolescent 
vaccination and CRPS incidence.   
The primary outcome was a diagnosis of CRPS, based the International Disease 
Classification of Diseases, Ninth Revision (ICD-9) codes for reflex sympathetic dystrophy (ICD-
9 codes 337.2, 337.2X) and algoneurodystrophy or Sudeck’s atrophy (ICD-9 code 733.7). We 
also identified cases of possible CRPS, based on ICD-9 codes for other idiopathic peripheral 
autonomic neuropathies (ICD-9 codes 337, 337.0, 337.00, 337.09, 337.1, 337.9) and neuralgia 
(ICD-9 code 729.2). Sensitivity analyses used a composite outcome of CRPS and possible CRPS 
cases.  
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We used causal diagrams to identify covariates of interest that are associated with 
adolescent vaccination and a CRPS diagnosis. We conditioned on female sex, insured status, and 
age in the study design, by restricting to insured girls at age 11. Covariates to include in our 
analyses included a history of physical trauma in the year prior to follow-up or diagnosis of 
physical trauma over the course of follow-up, as physical trauma is the strongest known risk 
factor for CRPS.48,50,64,98,99 Physical trauma was ascertained using ICD-9 codes for fractures, 
dislocations, sprains, motor vehicle accidents, and CPT codes for setting of fractures and 
dislocations and surgeries involving the musculoskeletal or nervous systems (Appendix 1).  
We first estimated the incidence rate and 95% confidence interval (CI) for CRPS using 
generalized estimating equations with a Poisson distribution and a robust variance estimator. 
Next, we assessed the associations of adolescent vaccinations with incident CRPS using time-
dependent Cox models to estimate hazard ratios (HR) and 95% CIs, comparing the hazard of 
CRPS between recently-vaccinated and previously-vaccinated or unvaccinated girls. We 
estimated crude HRs and trauma-adjusted HRs. 
Vaccination and trauma were considered time-dependent covariates. All girls were 
unexposed to all vaccinations at the beginning of follow-up. Girls who never received 
vaccination remained unexposed for the full follow-up period, while girls who received 
vaccination became exposed at the first date of a claim for vaccination. To assess the association 
of recent vaccination with CRPS, we considered girls exposed for 30 and 90 days after 
vaccination. At the end of the exposure window, vaccination status returned to unexposed. In the 
case of multiple doses of HPV vaccine, vaccination status returned to exposed after a subsequent 
dose was received, and remained exposed until the end of the exposure window. In a sensitivity 
analysis, we eliminated the exposure window to assess the hazard of CRPS following any recent 
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or non-recent vaccination; girls with claims for vaccination were considered exposed from the 
first date of vaccination and for the duration of follow-up. Trauma status was ascertained in a 
similar fashion. Girls with no claims for trauma remained unexposed for the duration of follow-
up, whereas girls with claims for trauma were considered exposed from the date of the claim and 
for the duration of follow-up. 
Next, we used time-dependent Cox models including interaction terms between 
vaccinations to assess the hazard of CRPS following receipt of 1) concomitant HPV vaccination 
versus HPV vaccination alone; and 2) concomitant Tdap+MenACWY+HPV versus 
Tdap+MenACWY. We estimated crude and trauma-adjusted HRs, and p-values to test the 
statistical significance of the vaccination interactions.  
Finally, we identified additional diagnoses from girls’ claims records that were positively 
associated with CRPS incidence. We identified the 400 most prevalent diagnoses among girls in 
the sample between the 11th birthday and the end of follow-up at CRPS diagnosis or censorship. 
We then created binary variables indicating whether or not each girl had the diagnosis. All 
diagnoses were considered time-dependent covariates using the method described above: girls 
without the diagnosis remained unexposed for the duration of follow-up, and girls with the 
diagnosis were considered exposed from the date of the diagnosis claim and for the duration of 
follow-up. We used time-dependent Cox models to estimate bivariate HRs for the association 
between each diagnosis and CRPS incidence; similar diagnoses were combined into a composite 
variable, and new HRs using the composite variable were estimated.  
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CHAPTER 4. PATTERNS OF USE OF HUMAN PAPILLOMAVIRUS AND OTHER 
ADOLESCENT VACCINES IN THE UNITED STATES 
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization 
Practices (ACIP) recommended routine meningococcal conjugate (MenACWY) and tetanus-
diphtheria-acellular pertussis (Tdap) vaccination for adolescents at age 11, in 2005 and 2006, 
respectively.10–12 ACIP subsequently recommended routine human papillomavirus (HPV) 
vaccination for females aged 11-12 on June 29, 2006, and for males aged 11-12 on October 21, 
2009.100–102 Phase III clinical trials of the prophylactic quadrivalent (4vHPV) and bivalent 
(2vHPV) HPV vaccines demonstrated over 90% efficacy against high-grade or greater cervical 
intraepithelial neoplasia (CIN-2+) associated with high-risk HPV (hrHPV) types 16 and 18.4,103  
Despite ACIP’s recommendations and strong evidence for the safety and efficacy of HPV 
vaccines, receipt of at least one dose of HPV vaccine (56.1%) among boys and girls aged 13-17 
lags behind receipt of Tdap (86.4%) or MenACWY (81.3%) vaccines in the United States, 
according to the 2016 nationally-representative National Immunization Survey-Teen (NIS-
Teen).15  
In the NIS-Teen surveys, parents report their children’s vaccination status and their 
children’s vaccination providers are contacted to confirm vaccination status. However, 
vaccination status might be misclassified if parents do not accurately recall their children’s 
vaccination providers, or if providers have inaccurate vaccination records.104 Further, the random 
digit dialing sampling strategy used for NIS-Teen results in low response rates, and the sample 
may not be generalizable to the U.S. population. Alternatively, insurance claims provide accurate 
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data on adolescent vaccination for millions of individuals, eliminating the need to review 
medical records and reducing recall and information biases. Further, insurance claims also allow 
monitoring of co-administration of vaccines on the same service date and trends over time in 
uptake of different vaccine combinations, which have only been recently reported in two studies 
using NIS-Teen data.105,106 
Here we present data from employer-sponsored insurance claims to describe patterns of 
use of HPV, Tdap, and MenACWY vaccination among vaccine-eligible girls and boys in the 
United States. Results from this study will identify gaps in vaccination coverage and can inform 
targeted adolescent vaccination promotion strategies. 
Methods 
Study population  
The  MarketScan® Commercial Claims and Encounters database captures patient-level 
medical claims provided by over 300 large employers in all 50 states, the District of Columbia, 
and Puerto Rico, including over 170 million unique enrollees since 1995.107 MarketScan 
provides patient demographic data, type and duration of health plan enrollment, claims for 
medical diagnoses and procedures using International Classification of Disease – 9th Revision 
(ICD-9) and Current Procedural Terminology (CPT) codes, respectively, and dates of medical 
services. We obtained MarketScan data between 2000 and 2014 from Truven Health Analytics. 
The study period began October 21, 2009 – when ACIP supported HPV vaccination for 
boys – marking the first opportunity for all eligible adolescents to receive all three recommended 
vaccines. We included girls and boys who 1) turned 11 years of age between 2009 and 2014; 2) 
had no prior history of adolescent vaccination; and 3) had at least one year of continuous 
insurance plan enrollment prior to the start of follow-up. 
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Data analysis 
We began observing adolescents from their 11th birthdays, when they became eligible for 
adolescent vaccination according to the ACIP recommendations. Because date of birth is 
protected health information, we searched monthly insurance enrollment files to identify the 
month in which the adolescent’s age changed, and then set the date of birth to the last day of that 
month. We followed adolescents from their estimated 11th birthdays (Time 0) until vaccination, 
disenrollment, or the end of the study period on December 31, 2014.  
We searched outpatient records for the first billed claim for 2vHPV (CPT code 90650) or 
4vHPV (CPT code 90649), Tdap (CPT code 90715, ICD-9 code 9939), and MenACWY (CPT 
code 90734). We excluded Tdap claims related to injuries or accidents (ICD-9 codes 037.X, 
87X-91X, V01-V02, all E codes) or receipt of antenatal care (ICD-9 codes V22.X-V39.X). 
While the HPV vaccination series includes multiple doses and MenACWY vaccine requires a 
booster, we only identified the first dose of each vaccine, as limited follow-up might prevent us 
from observing subsequent doses. Descriptive statistics summarized service-related 
characteristics at the time of vaccination, and the combinations of vaccines received by 
adolescents, including co-administered vaccines.  
For each vaccine, we estimated time to vaccination as the difference between Time 0 and 
the date of the first vaccination claim. We estimated total follow-up time as the difference 
between Time 0 and the date of service for adolescents who received vaccination; or the 
difference between Time 0 and the date of disenrollment or the end of the study period for 
adolescents who did not receive vaccination. We used generalized estimating equations with a 
Poisson distribution and a robust variance estimator to estimate vaccination incidence rates (IR) 
per 10,000 person-months of observation, incidence rate ratios (IRR) and 95% confidence 
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intervals (CI) for correlates of vaccination, and IRs of vaccine co-administration over time. 
Incidence rates and cumulative incidence were stratified by covariates of interest, including sex; 
region (Northeast, North Central, South, West, per the U.S. Census Bureau108); urbanicity, as 
defined by urban residence (metropolitan statistical area with population ≥50,000) or rural 
residence (micropolitan statistical area with population <50,000); receipt of primary care in the 
year prior to observation; and insurance plan type. We also plotted the cumulative incidence of 
receiving the first dose of HPV vaccine at age 11 or 12 (i.e. timely HPV vaccination), stratified 
by sex, urbanicity, region, and birth cohort. 
As many as 18 states had offered at least one adolescent vaccine free of charge, 
regardless of income level, since 2006 (Alaska, Connecticut, Hawaii, Idaho, Massachusetts, 
Maine, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Oregon, Rhode 
Island, South Dakota, Vermont, Washington, Wisconsin, and Wyoming).97 Adolescents from 
these states may have received vaccination without filing insurance claims, and thus their 
vaccination status would not be ascertained from MarketScan data. We conducted a sensitivity 
analysis excluding these states to assess potential bias due to under-ascertainment of vaccination 
status.  
Analyses were performed in SAS 9.3 (Cary, North Carolina). Proportional Venn 
diagrams were created using the eulerAPE application (Canterbury, UK).109 The University of 
North Carolina Office of Human Research Ethics approved this study. 
Results 
The analytic cohort included 1,691,223 adolescents: 822,544 girls and 868,669 boys. The 
median duration of follow-up was 16 months (interquartile range, 7-31 months) (Table 4.1). We 
observed at least one adolescent vaccination for 948,995 adolescents (56.1%) during the 
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observation period. Of the 922,137 adolescents who were enrolled until the end of the study 
period on December 31, 2014, 66.7% of them received any adolescent vaccination; of the 
769,086 adolescents who disenrolled during follow-up, 43.4% of them received any adolescent 
vaccination. Similar percentages of girls and boys received Tdap and MenACWY; however, the 
proportion of adolescents receiving HPV vaccination was higher in girls than boys (21.9% vs. 
15.1%) (Table 4.1).  Mean age at receipt of the first dose of HPV vaccine (11.8 years) was higher 
than that for Tdap and MenACWY (11.2 years for both), and girls received HPV vaccination 
relatively earlier than boys (mean age 11.7 years vs. 12.0 years). Among adolescents who 
received any vaccination, over 96% received Tdap or MenACWY vaccination within the ACIP-
recommended age range. In contrast, 81% of girls and 72% of boys received HPV vaccination 
within the ACIP-recommended age range (Table 4.2).  
One-quarter of adolescents who received any vaccination received all three recommended 
vaccines; 50.6% received Tdap and MenACWY only (Figure 4.1). For adolescents who received 
Tdap and MenACWY vaccination only, 92.3% received both concomitantly at their initial 
adolescent vaccination visit. However, only 24.1% of adolescents who received all three 
vaccinations received them concomitantly at the initial vaccination visit. Co-administration IRs 
of Tdap+MenACWY were higher than those for HPV+Tdap+MenACWY in each birth cohort, 
though IRs of both co-administration combinations increased steadily with each successive birth 
cohort (Figure 4.2).    
The IRs of HPV, Tdap, and MenACWY vaccination were lower in rural adolescents than 
urban adolescents (Table 4.3). The highest HPV vaccination IRs were observed in the West 
(117.2 95% CI: 116.3, 118.0), and the lowest HPV vaccination IRs were observed in the South 
(91.3, 95% CI: 90.8, 91.9). The West region had the lowest IRs of Tdap (IR: 404.7, 95% CI: 
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404.2, 407.1) and MenACWY (IR: 299.7, 95% CI: 297.8, 301.5) vaccination. The IRs of all 
vaccinations were lowest among adolescents with comprehensive insurance plans, and 
adolescents who had received any primary care in the year prior to the start of observation had 
higher IRs of all vaccinations than those without a primary care visit (Table 4.3).  
Overall, rural adolescents had lower IRs than urban adolescents of HPV (IRR: 0.76, 95% 
CI: 0.75, 0.77), Tdap (IRR: 0.58, 95% CI: 0.57, 0.58), and MenACWY vaccination (IRR: 0.53, 
95% CI: 0.53, 0.54) (Table 4.4). Rural adolescents in the North Central, South, and West regions 
were less likely than urban adolescents to receive HPV vaccination, whereas adolescents in the 
Northeast were more likely to receive HPV vaccination (IRR: 1.09, 95% CI: 1.05, 1.13) (Table 
4.4).  
 The cumulative incidence of timely HPV vaccination differed across subgroups (Figure 
4.3). Timely HPV vaccination was more frequent in girls versus boys, regardless of the time 
since start of follow-up. Adolescents residing in urban areas had a higher incidence of timely 
vaccination than adolescents residing in rural areas, and adolescents in the West had higher 
incidence of timely HPV vaccination than adolescents in the Northeast, North Central, or South 
regions. With more recent birth cohort, the cumulative incidence of timely HPV vaccination 
increased incrementally (Figure 4.3).  
After repeating these analysis excluding the 18 states that offered free universal 
adolescent vaccine coverage, we observed comparable vaccination proportions, vaccination 




Among 1.7 million vaccine-eligible adolescents with employer-sponsored insurance in 
the United States, we observed relatively lower IRs of HPV vaccination than Tdap or 
MenACWY vaccination in girls and boys. Further, HPV vaccination was more often delayed 
beyond the 11-12-year age range universally recommended by ACIP compared to Tdap and 
MenACWY vaccination. For all three recommended vaccines, rural adolescent residents were 
consistently less likely to be vaccinated than their urban counterparts in all geographical regions 
(South, Northeast, West) except in the Northeast. Our also data suggest birth cohort effects for 
co-administration of all three recommended vaccines, suggesting increased use of co-
administration over time and increased integration of HPV into the adolescent vaccination 
package over time.  
Similar to other studies, our data indicate that adolescents have frequent missed 
opportunities for HPV vaccination, namely clinic visits in which Tdap and/or MenACWY 
vaccines were administered.110 In our sample, though over half of adolescents had initiated 
adolescent vaccination, most adolescents had not received HPV vaccination by the end of 
follow-up. Of those who did, 23% received HPV vaccination outside of the ACIP-recommended 
age range (Table A1).  The National Health and Nutrition Examination Survey found that 43% of 
adolescents initiated HPV vaccination after or in the same year as sexual debut, increasing their 
risk for pre-vaccination HPV exposure.111 While ACIP recommends catch-up vaccination for 
adolescents older than 12, HPV vaccine effectiveness is highest prior to sexual debut.34 Among 
1,139 inner-city adolescent women in New York City, receiving HPV vaccination after age 15 
was associated with an increased hazard of high-grade cervical lesions relative to receiving 
vaccination prior to age 15.112 Thus, it is critical that providers recommend HPV vaccination in 
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boys and girls at the earliest opportunity, including sick visits and visits for other adolescent 
vaccinations.  
 Our study found that rural adolescents in the Northeast had higher IRs of HPV 
vaccination than their urban counterparts, though rural adolescents overall had lower IRs of 
vaccination with all three adolescent vaccines. The increase in HPV vaccination that we 
observed in rural, Northeastern adolescents could simply be a function of the smaller size of this 
region and fewer access barriers to vaccination for rural adolescents. Future research should 
identify specific barriers to vaccination in rural areas, besides economic factors, and differences 
in these factors by region. Provider factors in rural areas may influence whether they recommend 
HPV vaccination for their adolescent patients.113 A study comparing HPV vaccination 
recommendation behavior among 334 pediatricians in Appalachian and non-Appalachian 
counties of Kentucky and West Virginia found that Appalachian pediatricians were less likely to 
recommend HPV vaccination to their adolescent patients.114 Further, rural adolescents are more 
likely to receive care form a family physician rather than a pediatrician, and thus may be less 
likely to receive recommendations for HPV vaccination.115 All provider types who treat 
adolescents are encouraged to use CDC-developed messages to recommend HPV vaccination to 
eligible adolescents. In a national sample, CDC messages pertaining to the high prevalence of 
HPV infection, the importance of HPV vaccination for cancer prevention, and the efficacy of 
HPV vaccination were acceptable to caregivers who were reticent to vaccinate their 
adolescents.116  
Studies of caregivers’ attitudes toward HPV vaccination reveal concerns about vaccine 
safety and effectiveness, low perception of risk for HPV infection, and unwillingness to 
vaccinate adolescents who presumably are not sexually active against a sexually transmitted 
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infection.117–119 Adolescent health care providers should actively communicate the evidence-
based vaccination benefits to caregivers, particularly in regions that have low HPV vaccination 
coverage. Additionally, enhancing healthcare practices to facilitate vaccination can effectively 
increase HPV vaccination initiation. In a cluster randomized trial in Pennsylvania pediatric and 
family medicine practices, The 4 Pillars™ Practice Transformation Program, which promotes 
strategies such as patient notification for vaccination and establishing HPV vaccination 
champions in practices, was associated with greater increases in HPV vaccination initiation 
compared to control practices.120 
Our primary limitation is the short follow-up time (median 16 months) to observe 
vaccination receipt, preventing us from observing vaccination events that occurred after the end 
of follow-up. As a result, our longitudinal study yielded smaller vaccination incidence 
proportions than the vaccination coverage rates reported by NIS-Teen, which used cross-
sectional methods. We were also limited to reporting only the first instance of HPV and 
MenACWY vaccination to avoid drawing invalid conclusions about completion of these 
vaccination series. Second, there is a chance of misclassification of vaccination status due to the 
use of incorrect or alternate CPT or ICD-9 codes. We attempted to use all relevant vaccination 
codes to minimize under-ascertainment of vaccination receipt. However, MarketScan is not able 
to track all enrollees who switch between insurance plans, and thus historical vaccination data 
for adolescents who changed insurance might not be recognized. Third, because MarketScan 
represents employer-sponsored insurance claims, our results may not be generalizable to 
Medicaid and uninsured populations. We also are unaware of how many MarketScan enrollees 
are Medicaid-eligible, and might receive vaccination through channels that bill Medicaid. 
However, we observed comparable vaccination proportions and IRs after excluding states that 
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offer free adolescent vaccination, indicating that vaccination patterns are similar between 
adolescents with access to free vaccination and those without. These analyses should be 
replicated in Medicaid data to identify any disparities in vaccination patterns by insurance 
source. The Affordable Care Act of 2010 guarantees that immunizations are covered under all 
insurance plans.121 Deductible and other payment factors or provider selection factors, however, 
may influence vaccination decisions. Future research should assess the impacts of insurance 
coverage on adolescent vaccination. Finally, MarketScan lacks data on race and ethnicity, and 
we cannot know the degree to which regional differences are influenced by racial or ethnic 
variation in vaccination patterns.   
Strengths of this analysis include a large sample of adolescents in the United States and 
minimally-biased documentation of vaccine receipt. In identifying nearly one million vaccinated 
adolescents, we had sufficient power to identify correlates of vaccination status with precision. 
Using procedure and diagnosis codes from a large insurance claims database, we estimated 
vaccination IRs beginning at the age recommended by ACIP, allowing us to assess vaccination 
timeliness. We also made robust estimates of vaccination incidence using methods that account 
for differential follow-up times and censoring.  
Recent changes to HPV vaccine availability and recommendations may improve the 
uptake and impact of this vaccine. A 9-valent vaccine (9vHPV) preventing the seven hrHPV 
types most highly-associated with CIN2+ was approved by the FDA in December 2014, and 
recommended by ACIP for 11- and 12-year-olds in March 2015.122,123 This broad-coverage 
prophylactic vaccine promises to prevent even more cases of CIN-2+ attributed to hrHPV types 
when administered in a timely fashion. Future research can use MarketScan to monitor patterns 
of use of 9vHPV relative to 4vHPV and 2vHPV, and its concomitant use with Tdap and 
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MenACWY. Additionally, following a review of immunogenicity and effectiveness data, ACIP 
recommended in December 2016 that the HPV vaccination series be reduced to two doses from 
three for adolescents who vaccinate before age 15.124 This new recommendation may increase 
the acceptability of HPV vaccination due to a lower burden of clinic visits; reduce safety 
concerns associated with multiple doses of HPV vaccination; and simplify medical record-
keeping and vaccination status monitoring.  
Conclusions 
Offering HPV, Tdap, and MenACWY as a comprehensive adolescent vaccination 
platform could increase HPV vaccination to the same levels as Tdap and MenACWY.  Safety 
and immunogenicity research supports co-administration of HPV, Tdap, and MenACWY, and 
ACIP recommends co-administration of all three vaccines at age 11 or 12.125,126 HPV vaccination 
trends are encouraging, as indicated by more timely HPV vaccination and co-administration of 
all three recommended adolescent vaccines among adolescents born more recently. However, 
adherence to ACIP recommendations for HPV vaccination timing and HPV vaccination in boys 
remains particularly sub-optimal. Providers can educate caregivers about the benefits of 
vaccination, including information about recent disease outbreaks due to poor vaccine coverage. 
Providers should also avoid creating exceptions for HPV vaccination, stressing that all 
adolescent vaccines are safe, effective, and appropriate for 11- and 12-year-old girls and boys, 
unless contraindicated. Demand for and access to HPV vaccination for adolescents in rural areas 
must be improved. Early and concomitant vaccination can reduce the burden of adolescent 
preventive care in harder-to-reach areas.
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CHAPTER 5: HAZARD OF COMPLEX REGIONAL PAIN SYNDROME FOLLOWING 
HPV AND OTHER ADOLESCENT VACCINATION  
Introduction 
In the United States, the Centers for Disease Control and Prevention’s (CDC) Advisory 
Committee on Immunization Practices (ACIP) recommends universal HPV vaccination to girls 
and boys aged 11 or 12 as part of the adolescent vaccine platform, alongside tetanus-diphtheria-
acellular pertussis (Tdap) and meningococcal conjugate (MenACWY) vaccination.13 Phase III 
clinical trials and post-licensure surveillance have demonstrated the safety of all three adolescent 
vaccines, with no conclusive evidence for severe adverse events (SAE) following 
vaccination.4,5,22,127–130 Syncope and anaphylaxis have been associated with HPV vaccination, 
though these events are considered non-severe and rare, respectively.27,32,131 Suspected vaccine-
attributable SAE continue to be investigated, often following a safety signal from a case report or 
surveillance data. 
In 2013, Japanese media reported on 50 cases of girls experiencing symptoms of complex 
regional pain syndrome (CRPS) following HPV vaccination. Complex regional pain syndrome – 
formerly known as reflex sympathetic dystrophy, Subdeck’s atrophy, or algoneurodystrophy – is 
a rare disorder of the autonomic nervous system that causes pain and sudomotor, vasomotor, and 
trophic changes in the limbs.42 Onset of CRPS commonly follows trauma to the affected limb, 
such as a sprain or fracture, and less commonly follows an infection.42,43,45,47–50,64,70,72–75 The 
published literature contains two estimates of CRPS incidence, ranging from 20.6 cases/100,000 
person-years over 11 years in Olmstead County, Minnesota, USA, to 26.2/100,000 person-years 
over 10 years in The Netherlands.38,39 Pediatric CRPS (ages 5-17) primarily affects girls (~80% 
32 
of cases), predominantly affects a lower limb, often presents with comorbid mental illness or 
psychological distress, and is less likely than adult CRPS to follow a traumatic 
event.42,43,45,48,52,61,132–134  
CRPS is classified into two types, which share common diagnostic criteria but differ in 
their etiology. Unlike CRPS Type II, CRPS Type I cases do not present with demonstrable nerve 
damage, and thus Type I cases are more commonly linked to non-injurious events.37 Several case 
reports have described CRPS Type I (hereafter CRPS) cases following tetanus, influenza, 
rubella, and hepatitis B vaccination.44,65,77,79,80,135 Despite the lack of scientific evidence for an 
association between HPV vaccination and incident CRPS, public disapproval of HPV 
vaccination following media coverage of CRPS cases led the Japanese government to withdraw 
its recommendation for HPV vaccination in June 2013.66 HPV vaccination among eligible 
adolescents in Japan subsequently fell from 80% to <5% by the end of 2014.71,136  
The European Medicines Agency (EMA) recently concluded based on evidence from 
clinical trials, surveillance, and case reports that HPV vaccination does not cause CRPS.70,137 
However, to our knowledge, population-based studies have not been conducted to assess the risk 
of CRPS in adolescent girls, accounting for physical health status. A case series describing 
suspected CRPS in 40 Japanese girls reported that onset of CRPS symptoms often occurred long 
after the first dose of HPV vaccine (mean 5.475.00 months).68 Further, the report did not 
account for any history of traumatic injury among the cases, neglecting an essential component 
of CRPS etiology. It is critical to provide rigorous scientific evidence for HPV vaccine safety to 
prevent further refusal of this potentially life-saving vaccine, and to inform the public about 
potential risks and contraindications for HPV vaccination.  
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We present here the results of the first known epidemiological study of the association 
between HPV vaccination and CRPS incidence in adolescent girls in the United States, 
comparing the safety of HPV vaccination to that of Tdap and of MenACWY vaccination. We 
used a large private insurance claims database to identify sufficient adolescent CRPS cases for 
analysis.  
Methods 
Data source and study population  
The MarketScan® Commercial Claims and Encounters database captures patient-level 
medical claims for over 200 million unique enrollees in the United States since 1995.96 
MarketScan provides patient demographic data, type and duration of health plan enrollment, 
claims for medical diagnoses, procedures, and prescriptions using International Classification of 
Disease – 9th Revision (ICD-9), Current Procedural Terminology (CPT), Healthcare Common 
Procedure Coding System (HCPCS), and national drug codes (NDC), respectively, and dates of 
medical services. We obtained MarketScan claims data between January 1, 2000 and December 
31, 2014 from Truven Health Analytics.  
The study period began June 29, 2006 – the date of the ACIP recommendation for HPV 
vaccination in girls – and ended December 31, 2014. We included girls who 1) turned 11 years 
of age between 2006 and 2014; 2) had no prior claims for adolescent vaccination or CRPS; and 
3) had at least one year of continuous insurance plan enrollment prior to the 11th birthday. We 
observed girls from the 11th birthday until the date of a claim for a CRPS diagnosis, or 
censorship at disenrollment from their insurance plan or December 31, 2014. For girls with 
multiple continuous enrollment periods, we restricted observation to the enrollment period that 
included the 11th birthday. Because date of birth is protected health information, we searched 
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monthly insurance enrollment files to identify the month in which the adolescent’s age changed, 
and then set the date of birth to the last day of that month.  
Covariate ascertainment 
The primary outcome was a diagnosis of CRPS, based the International Disease 
Classification of Diseases, Ninth Revision (ICD-9) codes for reflex sympathetic dystrophy (ICD-
9 codes 337.2, 337.2X) and algoneurodystrophy or Sudeck’s atrophy (ICD-9 code 733.7). We 
also identified cases of possible CRPS, based on ICD-9 codes for other idiopathic peripheral 
autonomic neuropathies (ICD-9 codes 337, 337.0, 337.00, 337.09, 337.1, 337.9) and neuralgia 
(ICD-9 code 729.2). Sensitivity analyses used a composite outcome of CRPS and possible CRPS 
cases.  
The primary exposures were claims for adolescent vaccination, based on Current 
Procedural Terminology (CPT) codes for administration of 2vHPV (CPT code 90650) or 
4vHPV(CPT code 90649); Tdap vaccine (CPT code 90715); or MenACWY vaccine (CPT code 
90734). Secondary exposures included 1) concomitant administration of HPV vaccine with one 
or more of Tdap, MenACWY, or influenza (CPT codes 4037F, 90658-90688, 90724, 90737) 
vaccines; and 2) concomitant administration of Tdap and MenACWY vaccines with HPV 
vaccine. Only the first instances of Tdap and MenACWY vaccination were considered for this 
analysis. 
The primary confounder of interest was a historical diagnosis of physical trauma or an 
occurrence of physical trauma during follow-up. Trauma is positively associated with CRPS 
incidence, and may also be positively associated with adolescent vaccination through increased 
opportunities for vaccination during sick visits.138,139 Historical trauma was measured in the year 
prior to the 11th birthday, and occurrence of trauma during follow-up was measured from the 11th 
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birthday until the end of follow-up at CRPS diagnosis or censorship. Physical trauma was 
ascertained using ICD-9 codes for fractures, dislocations, sprains, and motor vehicle accidents; 
CPT codes for setting of fractures and dislocations; and CPT codes for surgeries of the 
musculoskeletal or nervous systems in inpatient and outpatient settings (Appendix 1).  
Statistical analysis 
We first estimated the incidence rate and 95% confidence interval (CI) for CRPS using 
generalized estimating equations with a Poisson distribution and a robust variance estimator. 
Next, we assessed the associations of adolescent vaccinations with incident CRPS using time-
dependent Cox models to estimate hazard ratios (HR) and 95% CIs, comparing the hazard of 
CRPS between vaccinated and unvaccinated girls. We estimated crude HRs and trauma-adjusted 
HRs. 
Vaccination and trauma were considered time-dependent covariates. All girls were 
unexposed to all vaccinations at the beginning of follow-up. Girls who never received 
vaccination remained unexposed for the full follow-up period, while girls who received 
vaccination became exposed at the first date of a claim for vaccination. To assess the association 
of recent vaccination with CRPS, we considered girls exposed for 30 and 90 days after 
vaccination. At the end of the exposure window, vaccination status returned to unexposed. In the 
case of multiple doses of HPV vaccine, vaccination status returned to exposed after a subsequent 
dose was received, and remained exposed until the end of the exposure window. In a sensitivity 
analysis, we eliminated the exposure window to assess the hazard of CRPS following any recent 
or non-recent vaccination; girls with claims for vaccination were considered exposed from the 
first date of vaccination and for the duration of follow-up. Trauma status was ascertained in a 
similar fashion. Girls with no claims for trauma remained unexposed for the duration of follow-
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up, whereas girls with claims for trauma were considered exposed from the date of the claim and 
for the duration of follow-up. 
Next, we used time-dependent Cox models including interaction terms between 
vaccinations to assess the hazard of CRPS following receipt of 1) concomitant HPV vaccination 
versus HPV vaccination alone; and 2) concomitant Tdap+MenACWY+HPV versus 
Tdap+MenACWY. We estimated crude and trauma-adjusted HRs, and p-values to test the 
statistical significance of the vaccination interactions.  
Finally, we identified additional diagnoses from girls’ claims records that were positively 
associated with CRPS incidence. We identified the 400 most prevalent diagnoses among girls in 
the sample between the 11th birthday and the end of follow-up at CRPS diagnosis or censorship. 
We then created binary variables indicating whether or not each girl had the diagnosis. All 
diagnoses were considered time-dependent covariates using the method described above: girls 
without the diagnosis remained unexposed for the duration of follow-up, and girls with the 
diagnosis were considered exposed from the date of the diagnosis claim and for the duration of 
follow-up. We used time-dependent Cox models to estimate bivariate HRs for the association 
between each diagnosis and CRPS incidence; similar diagnoses were combined into a composite 
variable, and new HRs using the composite variable were estimated. Selected diagnoses of 
interest are displayed in a forest plot, organized by illness category. 
All analyses were conducted in SAS version 9.3 (SAS Institute, Cary, North Carolina, 




 The present analysis included 1,232,572 girls. The median duration of follow-up from the 
11th birthday until CRPS diagnosis or censorship was 1.66 years (interquartile range: 0.67-3.25 
years). The incidence proportion of HPV vaccination was 23.3%, compared to 50.4% for Tdap 
and 44.0% for MenACWY vaccination (Table 5.1). 4vHPV was administered in over 98% of all 
HPV vaccinations. We identified 563 cases of CRPS, with an incidence rate of 20.57 per 
100,000 person-years. An additional 1,689 possible CRPS cases were identified for use in 
sensitivity analyses (Table 5.1).  
The relative hazard of CRPS was not elevated within the 30 days following any 
adolescent vaccination, in crude analysis or after adjustment for trauma (Table 5.2). Within the 
90 days following vaccination, HPV vaccination was associated with an increased hazard of 
CRPS (HR: 1.51, 95% CI: 1.09, 2.09), but this association was null after adjustment for trauma 
(adjusted HR: 1.30, 95% CI: 1.00, 1.93). After adjustment for trauma, MenACWY vaccination 
(adjusted HR: 1.54, 95% CI: 1.05, 2.28) and concomitant Tdap+MenACWY vaccination 
(adjusted HR: 1.67, 95% CI: 1.08, 2.60) were positively associated with CRPS in the 90 days 
following vaccination (Table 5.2). 
In sensitivity analyses eliminating the exposure window, we found no significant 
association between HPV vaccination at any time in the past and CRPS incidence (Table 5.3). 
We observed crude associations between Tdap vaccination, MenACWY vaccination, and 
concomitant Tdap+MenACWY vaccination and incident CRPS (Table 5.3). However, after 
adjustment for trauma, the HRs for Tdap vaccination (adjusted HR: 1.09, 95% CI: 0.91, 1,29) 
and MenACWY vaccination (adjusted HR: 1.19, 95% CI: 1.00, 1.42) became non-significant. 
The adjusted HR for concomitant Tdap+MenACWY vaccination remained significantly elevated 
after adjustment (adjusted HR: 1.27, 95% CI: 1.06, 1.51) (Table 5.3).  
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 We observed a non-significant increase in CRPS hazard comparing concomitant HPV 
vaccination to HPV vaccination alone in the past 30 days (adjusted HR: 2.30, 95% CI: 0.80, 
6.56) or 90 days (adjusted HR: 1.62, 95% CI: 0.85, 3.06,) (Table 5.4). We also observed a non-
significant increase in CRPS hazard comparing concomitant Tdap+Men+HPV vaccination to 
concomitant Tdap+MenACWY vaccination in the past 30 days (adjusted HR: 4.15, 95% CI: 
0.69, 24.48) or 90 days (adjusted HR: 1.35, 95% CI: 0.52, 3.51) (Table 5.4). The p-values for all 
interaction terms exceeded the 0.05 significance level, indicating no excess CRPS hazard 
associated with concomitant administration of multiple vaccines. 
When including possible CRPS cases in the above analyses, we observed similar trends 
in which observed associations between HPV, Tdap, MenACWY, or Tdap+MenACWY 
vaccination at any time in the past were attenuated to the null value after adjusting for trauma. 
We also saw no association between any vaccination and the 30- or 90-day hazard of CRPS or 
possible CRPS.  
Crude HRs for positive associations between prior diagnoses and incident CRPS are 
displayed in Figure 5.1. Of the 400 most prevalent prior diagnoses among girls in the sample, 
258 were positively associated with incident CRPS; 209 of these were condensed into broader 
categories, listed on the left side of the figure. The strongest predictors of CRPS were 
musculoskeletal diagnoses. Girls with injuries, including a fracture, sprain, strain, dislocation, 
contusion, or wound, had at least twice the hazard of CRPS compared to girls without injuries, 
and girls with injuries to the lower limb had a 12-fold hazard of CRPS compared to girls without 
lower limb injuries (HR: 12.4, 95% CI: 10.4, 14.7) (Figure 5.1). Likewise, pain in the lower 
joints showed a similar magnitude of association with CRPS (HR: 11.8, 95% CI: 8.09, 16.6) 
(Figure 5.1). Girls with anxiety and adjustment disorders had three times the hazard of CRPS 
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compared to girls without (HR: 3.12, 95% CI: 2.41, 4.04). Common pediatric illnesses, such as 
asthma, respiratory and ear infections, asthma, allergies, menstrual irregularities, anemia, and 
skin disorders, were also positively associated with CRPS (Figure 5.1).  
Discussion 
 This is the first population-based, epidemiological study to assess the association between 
adolescent vaccination and incident CRPS. The hazard of CRPS was not significantly elevated 
following HPV vaccination at any time in the past, or in the past 30 or 90 days. We observed an 
elevated hazard of CRPS following MenACWY vaccination and concomitant Tdap+MenACWY 
vaccination in the past 90 days, and following concomitant Tdap+MenACWY vaccination at any 
time in the past. However, we cannot rule out residual confounding of these associations due to 
unobserved factors; expert opinion suggests that CPRS cases occurring more than 30 days after 
vaccination are unlikely to be caused by vaccination.140 We identified additional health status 
indicators that were positively associated with a CRPS diagnosis. Common pediatric illnesses 
and healthcare seeking behavior may also confound associations between vaccination and CRPS, 
and these health indicators should be assessed in future epidemiologic studies of risk factors for 
CRPS.  
We observed CRPS incidence rates comparable to those reported in Minnesota, USA and 
The Netherlands, both of which included adult CRPS cases.38,39 To our knowledge, our incidence 
rate estimate is the only one reported in the literature to be restricted to pediatric cases. Another 
key difference between our estimates and prior estimates is the choice of data source: our data 
reflect healthcare usage among insured individuals, whereas previous estimates included 
population-level healthcare usage data, irrespective of insurance status. As a result, our sample 
may be biased toward heavier users of healthcare. In accordance with the CRPS literature, we 
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found that CRPS was highly associated with indicators of ill health. Among CRPS cases in our 
sample, 79% had an occurrence of trauma prior to CRPS diagnosis. Also consistent with prior 
reports, a large proportion of CRPS cases in our sample (36%) had a history of mental illness 
diagnosis or treatment prior to CRPS onset (Appendix 2), supporting a potential psychological 
component in CRPS development.45,48,98,132–134 In a Danish case-control study of 316 females 
seeking care for adverse events following HPV vaccination, matched with 163,910 vaccine 
recipients not reporting adverse events, cases were more likely to utilize primary care, including 
phone or email consultations with providers (odds ratio: 2.38, 95% CI: 1.44, 3.92) and requests 
for laboratory analysis (odds ratio: 1.73, 95% CI: 1.29, 2.32)  prior to vaccination.141 The role of 
somatization or conversion disorders should be considered in CRPS diagnosis and treatment, and 
psychotherapy in addition to physical therapy remains a cornerstone of successful pediatric 
CRPS management.44–62 
Several biological mechanisms for CRPS have been proposed. First, immune activation 
and triggering of inflammatory pathways may cause the pain, heat, redness, and swelling that is 
common in acute CRPS.42,142,143 In a German hospital-based study, levels of pro-inflammatory 
molecules interleukin-8 and Substance P were increased in CRPS patients compared to healthy 
patients.144 Second, in individuals with underlying dysfunction of the autonomic nervous system, 
stimulation of dysfunctional nerve fibers, e.g. from injuries, can trigger the disproportional pain 
sensations that are characteristic of CRPS.86,145,146 Autonomic dysfunction may be hereditary; a 
case series from The Netherlands described multiple CRPS cases in families, with an earlier 
onset and more severe presentation in familial cases compared to sporadic cases.147 Third, 
prolonged immobilization of the arm due to pain at the injection site can lead to decreased blood 
flow and trophic changes to the limb, resembling symptoms of CRPS; injection site pain may be 
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elevated following concomitant vaccination.148–150  Future research should continue to search for 
the pathophysiological mechanisms of CRPS, including mechanisms that might be associated 
with vaccination (e.g. inflammatory responses following vaccination and nerve injuries caused 
by needles).  
Study limitations include the inability to validate CRPS diagnoses using additional 
diagnostic data, as this was not available from MarketScan insurance claims. The diagnostic 
criteria endorsed by the International Association for the Study of Pain (IASP) rely on clinical 
signs and symptoms that are seldom reported in outpatient medical claims. Further, these criteria 
were validated in adults, despite a distinct phenotype and prognosis in pediatric cases cases.42,49 
As a result, it is possible that our CRPS incidence estimate, as well as the number of cases 
identified in Japan, is over-estimated. Two prior studies, in which CRPS cases identified from 
healthcare databases were validated using medical records and expert review, found that 43-65% 
of CRPS cases did not fulfill the diagnostic criteria.38,39 We were also unable to determine if 
trauma occurred in the same limb(s) affected by CRPS, due to missing data on which limb was 
affected. Finally, residual confounding by other health indicators may account for the positive 
associations that we observed between CRPS hazard and MenACWY and Tdap+MenACWY 
associations in the past 90 days (e.g. infections).  
The primary strength of this study is the ability to identify many cases of a rare disease 
using employer-sponsored insurance claims. MarketScan also provides accurate and unbiased 
data on vaccinations and dates of service, allowing us to assess multiple vaccination 
combinations. We used sophisticated time-to-event models to estimate the hazard of CRPS 
within pre-specified windows following vaccination, providing evidence that CRPS risk is not 
elevated in the days proximal to a vaccination event and casting doubt on the biological 
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plausibility of vaccine-induced CRPS. Establishing time frames is critical, as the Japanese case 
study included cases that happened a median of 5.47 months after vaccination, reducing the 
probability that these events were incited by the vaccination event.68 Finally, ours is the first 
epidemiological study to adjust for the occurrence of trauma when assessing the association of 
vaccination with CRPS. While there is not strong evidence from the literature that trauma or ill 
health is associated with increased vaccination rates, we posit that trauma is more likely to 
influence vaccination rates than the converse. We feel confident that trauma is not along the 
causal pathway between vaccination and CRPS and thus we did not inappropriately adjust for a 
mediating variable. Doing so may induce a spurious association between vaccination and CRPS, 
or may mask a true association that is mediated by trauma. 
 Our results support the continued administration and co-administration of recommended 
vaccines to adolescents in the United States. We recommend that this study be replicated using 
Japanese insurance claims to confirm these findings, and to identify any potential ecological 
differences between adolescents in the United States and Japan. Future research directions 
include conducting expert medical record reviews of CRPS cases to validate diagnoses against 
highly-specific criteria; and assessment of vaccination practices – including the number of 
injections administered and in which limb – and their association with an increased pain response 
and subsequent CRPS development. Future studies should also estimate absolute differences in 
CRPS risk and a “number needed to harm” to estimate the excess CRPS caseload associated with 
vaccination. Given the rarity of adolescent CRPS, any potential increase in CRPS cases would 





 Our findings, in conjunction with those published the EMA, do not support any changes 
to existing HPV vaccination recommendations with respect to an association with CRPS. While 
we observed associations between CRPS and MenACWY vaccination and concomitant 
Tdap+MenACWY vaccination, we suggest further study to identify additional confounders of 
these relationships. Further study on suspected CRPS risk factors is warranted, as the discovery 
of independent risk factors could lead to development of CRPS risk assessment tools, and could 
potentially identify contraindications for adolescent vaccination. Presently, providers should 
continue to follow ACIP recommendations for injection procedures and for managing syncope, 
anaphylaxis, and pain following vaccination.13
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CHAPTER 6: CONCLUSIONS 
Summary of findings 
 This work found that among 1.7 million age-eligible adolescents in the United States, 
HPV vaccination uptake is lower than Tdap and MenACWY vaccination uptake, in agreement 
with nationwide vaccination coverage rates. The age at first uptake of HPV vaccination is older 
than that for Tdap and MenACWY vaccination, indicating that many adolescents are receiving 
HPV vaccination after the ACIP-recommended age, and are at increased risk for HPV infection 
and harmful sequelae. By the end of follow-up in our sample, only one-quarter of vaccinated 
adolescents had received all three ACIP-recommended vaccines.  
 Geographic factors were associated with adolescent vaccination, wherein rural 
adolescents were less likely than urban adolescents to receive HPV, Tdap, and MenACWY 
vaccination. However, the effect of urbanicity on vaccination rates was modified by region: 
whereas rural adolescents in the North Central, South, and West regions were less likely to 
receive adolescent vaccination, rural adolescents in the Northeast region were more likely to 
receive HPV vaccination.  
 We observed some positive trends in HPV vaccination by birth cohort. Concomitant 
administration of HPV vaccine alongside Tdap and MenACWY increased steadily with each 
successive birth cohort, as did the cumulative incidence of timely HPV vaccination at age 11 or 
12. 
 In over 1.2 million adolescent girls, we observed 563 cases of CRPS, for an incidence 
rate of 20.6/100,000 person-years. We found no significant increase in the hazard of CRPS 
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comparing girls with and without recent adolescent vaccination, or concomitant adolescent 
vaccination, within the past 30 or 90 days. Sensitivity analyses also showed that incidence of 
CRPS at any time following adolescent vaccination was heavily confounded by experiencing or 
having a history of physical trauma. While bivariate analyses indicated a positive association 
between Tdap and MenACWY vaccination and CRPS at any time since vaccination, adjustment 
for trauma attenuated all associations toward the null value. We also found that concomitant 
administration of Tdap, MenACWY, or influenza vaccine with HPV vaccine was not associated 
with an increased hazard CRPS or possible CRPS within 30 or 90 days, nor was concomitant 
administration of HPV with Tdap+MenACWY.  
We did observe positive associations between MenACWY vaccination and 
Tdap+MenACWY vaccination and the hazard of CRPS after 90 days, as well as 
Tdap+MenACWY vaccination and the hazard of CRPS at any time following vaccination. 
However, these associations were attenuated after adjustment for trauma, and thus we cannot 
rule out residual confounding due to other health-related factors. In a series of bivariate analyses, 
we identified lower limb injuries as the primary risk factor for CRPS, in agreement with prior 
studies and current understandings on CRPS etiology in adolescents. Common pediatric illnesses 
were also found to be associated with CRPS incidence, and may also confound observed 
associations between vaccination and CRPS. Infections, asthma and allergies, and mental illness 
may be targets for future research to better understand the etiology of CRPS. 
Public health significance 
The low rates of HPV vaccination relative to Tdap and MenACWY vaccination indicate 
vast missed opportunities for HPV vaccination. The findings from our study can be used to 
identify targeted and tailored strategies to increase the use of all recommended adolescent 
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vaccines, and specifically HPV vaccine. In general, improved communication between providers 
and caregivers can provide needed information on the effectiveness and safety of HPV vaccines 
to help caregivers make informed vaccination decisions.  
From a vaccine policy standpoint, states can develop programs to improve availability of 
vaccines or access to vaccination. While our study population includes insured adolescents who 
have greater financial access to vaccination, there may be geographical or logistical barriers that 
prevent widespread vaccination in certain areas. For example, rural areas in large geographic 
regions, such as the North Central, South, and West regions, may be more isolated from health 
care centers or providers who offer HPV vaccination. HPV vaccination in boys is also lower than 
in girls, despite a gender-neutral HPV vaccination recommendation in the United States. HPV 
vaccination in boys not only reduces the risk for anal, penile, and oropharyngeal cancer, but also 
prevents transmission to girls and contributes to reducing the burden of high-risk HP V and 
cervical precancer. To see a continuation of the positive cohort effects we observed with respect 
to timely HPV vaccination and concomitant administration of HPV with other vaccines, a 
combination of approaches will be needed to improve access to and demand for HPV vaccination 
among adolescents. 
A growing evidence base for HPV vaccine safety with respect to SAEs can improve 
perceptions of the vaccine among providers and caregivers and allay fears that HPV vaccines are 
riskier than other commonly-administered adolescent vaccines. Our study supports prior 
evidence from clinical trials and post-licensure surveillance to show that HPV vaccination does 
not confer an elevated risk of CRPS or CRPS-like conditions. Known risk factors for CRPS are 
also associated with receipt of HPV vaccination through increased utilization of the health care 
system, and thus crude associations between vaccination and CRPS appeared positive in our 
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analyses. The case study that contributed to the withdrawal of HPV vaccination in Japan 
neglected to document the health history of CRPS patients, and was remiss in attributing the 
patients’ symptoms exclusively to HPV vaccination. Our findings demonstrate that physical 
trauma accounts for much of the observed association between vaccination and CRPS, making 
the case for conditioning on these variable in future epidemiological studies of CRPS.  Further, 
case studies that report on SAEs following vaccination should take care to thoroughly document 
patients’ medical history to expound upon prior or existing conditions that may account for the 
observed signs and symptoms. Rigorous research and responsible reporting thereof can prevent a 
recurrence of the situation in Japan, in which decisions that affect millions of vulnerable 
individuals were made in response to public perceptions and in the absence of sufficient 
scientific evidence.  
Strengths 
The primary strength of this study include a large sample to 1) identify trends in 
adolescent vaccination and 2) identify rare SAEs for analysis. We had sufficient numbers of 
adolescents to be able to stratify by key characteristics and identify coverage gaps by region and 
urbanicity, as well as observe cohort effects for HPV vaccination practices. We were also able to 
conduct the first population-based epidemiological study of HPV vaccination and CRPS, 
providing evidence to reinstate the HPV vaccination recommendation in Japan and continuing to 
provide assurance that SAEs following vaccination are rare and are likely not associated with the 
vaccination itself. Using healthcare data allowed us to assess confounding due to other health-
related factors that we could capture in insurance claims records. For both aims, insurance claims 
afforded us data that does not require sampling and is more accessible than survey data, and is 
not subject to the same recall biases as survey data. 
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We used rigorous longitudinal methods to estimate associations between vaccination and 
CRPS, accounting for time since vaccination and administration of multiple vaccines 
concomitantly. Having dates of service for vaccination, CRPS diagnosis, and other health 
encounters of interest provided clarity on the temporality of all covariates for a proper 
epidemiological study of post-vaccination SAEs.   
Limitations 
 Limitations of this work include limited follow-up time for observing vaccination events 
of interest. As a result, we were unable to assess HPV dose completion for all adolescents. Given 
the open nature of our cohort, we were also unable to assess vaccine coverage per se, and instead 
estimated vaccination proportions that are not directly comparable to the coverage rates reported 
in the NIS-Teen survey. Insurance claims also lack race/ethnicity information and prevent us 
from identifying potential cultural differences in vaccination practices across the United States. 
Given that our study population is insured by an employer-sponsored plan, our studies’ findings 
are not likely generalizable to low-income or Medicaid-eligible populations.  
 CRPS is a poorly-understood outcome that is diagnosed on strictly clinical criteria. 
Without a straight-forward diagnostic tool, and given the low specificity of early versions of the 
IASP diagnostic criteria, misdiagnosis of CRPS cases is common. Prior studies of CRPS 
incidence in Minnesota, USA and The Netherlands also used healthcare databases to identify 
CRPS cases, but validated these diagnoses using electronic medical records and expert opinion, 
subsequently reduced the initial case counts in both studies.38,39 Without access to medical 
records, and without systematic documentation of signs and symptoms in insurance claims, we 
were unable to validate our CRPS cases. Insurance claims also lack the richness of data of 
medical records, preventing us from clarifying the physiological mechanisms of CRPS 
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development, e.g. if the limb that experienced trauma is the same that experienced CRPS 
symptoms.  
Future research directions 
Future research on adolescent HPV vaccination in the United States should aim to 
understand regional differences in vaccination patterns, with specific focus on availability and 
access to vaccines. Prior studies have identified caregivers’ barriers to HPV vaccination, as well 
as effective messages from providers to promote acceptance of HPV vaccination. Federal and 
local public health entities should develop training and educational materials for providers to 
engage in evidence-based communications with caregivers about the importance of adolescent 
vaccination. Additional data will be needed to identify further characteristics adolescents who do 
not receive HPV vaccination and to create targeted interventions to improve uptake. Other 
factors of interest include race/ethnicity, primary language spoken at home, education status of 
caregivers, and religion. We should continue to monitor vaccination trends throughout the United 
States, including patterns of use of the new 9-valent HPV vaccine once sufficient utilization data 
become available.   
The safety of HPV and other adolescent vaccines must be continuously examined. Now 
that HPV vaccines have been approved in the United States for over 10 years, uptake rates are 
increasing to approach the rates of Tdap and MenACWY vaccines. However, anxiety around 
HPV vaccine safety persists, and the scientific community must take seriously any reports of 
SAEs following vaccination. Rigorous safety studies can reassure policy-makers, providers, and 
caregivers that HPV vaccination is not associated with SAEs, or can identify specific risk factors 
for SAEs that may be incorporated in vaccination recommendations. Though not without 
limitations, insurance claims data have proven to be useful data sources for identifying rare 
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events, and can be used to assess vaccine safety with respect to myriad outcomes. Safety studies 
for rare events of unknown etiology, like CRPS and many auto-immune diseases, can be 
supplemented by thorough medical record reviews that provide detailed data on health history, 
signs, symptoms, and diagnostics. Triangulation of safety data from multiple sources can provide 
the most comprehensive evidence in favor of life-saving adolescent vaccination, or can provide 






Table 4.1. Incidence of HPV, Tdap, and MenACWY vaccination among adolescents in the MarketScan database, 2009-2014 







Median duration (IQR) of follow-up, months 16.1 (7.1, 31.2) 16.1 (7.1, 31.2) 16.1 (7.1, 31.2) 
    
Cumulative incidence (incidence proportion) of adolescent 
vaccination 
   
     Any vaccination 948,995 (56.1%) 467,355 (56.8%) 481,640 (55.5%) 
     HPV vaccination 311,110 (18.4%) 180,373 (21.9%) 130,737 (15.1%) 
     Tdap vaccination 880,586 (52.1%) 431,814 (52.5%) 448,772 (51.7%) 
     MenACWY vaccination 774,132 (45.8%) 378,377 (46.0%) 395,755 (45.6%) 








Mean age (SD) at first adolescent vaccination 11.5 (0.8) 11.5 (0.8) 11.5 (0.8) 
     HPV vaccination (n=311,110) 11.8 (1.0) 11.7 (1.0) 12.0 (1.1) 
     Tdap vaccination (n=880,586) 11.2 (0.5) 11.2 (0.5) 11.3 (0.5) 
     MenACWY vaccination (n=774,132)  11.2 (0.6) 11.3 (0.6) 11.3 (0.6) 
Eligible 11-year-olds are those who are continuously enrolled in an insurance plan as of the midpoint of their 11th year and had not previously received 
HPV/Tdap/MenACWY vaccines. The Advisory Committee on Immunization Practices recommends all three vaccines beginning at age 11. 
Abbreviations: HPV=human papillomavirus vaccine; Tdap=tetanus-diphtheria-acellular pertussis vaccine; MenACWY=meningococcal conjugate vaccine; 







Table 4.2. Service-related characteristics at the time of vaccination among adolescents who received HPV, Tdap, or MenACWY 
vaccination, 2009-2014 (N=948,995) 
 Girls (n=467,355) Boys (n=481,640) 
Characteristic 
HPV 




(n=130,737) Tdap (n=448,772) 
MenACWY 
(n=395,755) 
Age at initiation 
(years) n % n % n % n % n % n % 
   11 96,102 53.3% 342,704 79.4% 292,327 77.3% 57,760 44.2% 351,439 78.3% 302,512 76.4% 
   12 50,465 28.0% 80,015 18.5% 72,448 19.1% 36,497 27.9% 86,199 19.2% 78,131 19.7% 
   13 21,240 11.8% 7,398 1.7% 9,759 2.6% 21,547 16.5% 9,271 2.1% 11,187 2.8% 
   14 10,101 5.6% 1,423 0.3% 3,131 0.8% 11,798 9.0% 1,645 0.4% 3,225 0.8% 
   15 2,408 1.3% 269 0.1% 653 0.2% 3,065 2.3% 209 0.0% 625 0.2% 
   16 57 0.0% 5 0.0% 59 0.0% 70 0.1% 9 0.0% 75 0.0% 
Provider type at 
vaccination              
   Pediatrician 117,924 65.4% 279,333 64.7% 261,582 69.1% 90,361 69.1% 291,851 65.0% 275,378 69.6% 
   Family practice 26,179 14.5% 63,321 14.7% 43,310 11.4% 15,745 12.0% 66,556 14.8% 45,543 11.5% 
   Multi-specialty  
   physician group 7,512 4.2% 17,303 4.0% 14,175 3.7% 5,325 4.1% 17,899 4.0% 14,717 3.7% 
   Medical doctor 7,198 4.0% 18,670 4.3% 15,969 4.2% 5,078 3.9% 19,338 4.3% 16,686 4.2% 
   Perinatal medicine 2,532 1.4% 6,319 1.5% 5,736 1.5% 1,662 1.3% 6,532 1.5% 5,916 1.5% 
   Internal medicine  3,375 1.9% 8,236 1.9% 6,516 1.7% 2,328 1.8% 8,752 2.0% 6,919 1.7% 
   Nurse  3,265 1.8% 8,032 1.9% 6,398 1.7% 1,790 1.4% 6,756 1.5% 5,219 1.3% 
   Other* 6,989 3.9% 16,618 3.8% 13,230 3.5% 5,264 4.0% 16,892 3.8% 13,620 3.4% 
   Missing 5,399 3.0% 13,982 3.2% 11,461 3.0% 3,184 2.4% 14,196 3.2% 11,757 3.0% 
HPV vaccine type 
received             
   Quadrivalent 177,831 98.6% - - - - 130,603 99.9% - - - - 
   Bivalent 2,542 1.4% - - - - 134 0.1% - - - - 
Abbreviations: HPV=human papillomavirus vaccine; Tdap=tetanus-diphtheria-acellular pertussis vaccine; MenACWY=meningococcal conjugate vaccine. 
*Other providers include: acute care hospital, allergy & immunology, anesthesiology, birthing center, cardiothoracic surgery, chiropractor, dental specialist, dentist, 
dermatology, emergency medicine, endocrinology & metabolism, geriatric medicine, hospice facility, hospitalist, infectious diseases, laboratory, medical technician, neurology, 
obstetrician/gynecologist, ophthalmology, osteopathic medicine, pathology, pediatric allergy & immunology, pediatric cardiology, pediatric emergency medicine, pediatric 
hematology-oncology, pediatric infectious diseases, pediatric pulmonology, pediatric surgery, physical medicine and rehabilitation, physician assistant, podiatrist, preventive 







Table 4.3. Incidence rates per 10,000 person-months of HPV, Tdap, and MenACWY vaccination among adolescents by selected 
characteristics, 2009-2014 (n=1,691,223) 
  HPV Tdap MenACWY 
  IR (95% CI) IR (95% CI) IR (95% CI) 
Metropolitan statistical area    
   Urban (n=1,423,989) 103.9 (103.5, 104.2) 527.5 (526.0, 528.9) 414.9 (413.7, 416.1) 
   Rural (n=231,792) 78.8 (77.9, 79.6) 304.5 (302.3, 306.8) 221.8 (220.0, 223.6) 
   Missing (n=35,442)       
Region of residence    
   Northeast (n=247,991) 104.3 (103.4, 105.2) 685.3 (680.3, 690.3) 526.8 (532.1, 530.6) 
   North Central (n=426,605) 99.3 (98.7, 100.0) 542.8 (540.1, 545.4) 417.2 (415.0, 419.3) 
   South (n=637,009) 91.3 (90.8, 91.8) 446.9 (445.1, 448.7) 364.1 (362.5, 365.7) 
   West (n=343,161) 117.2 (116.3, 118.0) 404.7 (402.4, 407.1) 299.7 (297.8, 301.5) 
  Missing (n=36,457)       
Insurance plan type    
   Preferred provider plan (n=1,043,991) 96.8 (96.4, 97.3) 484.5 (482.9, 486.1) 373.4 (372.2, 374.7) 
   Comprehensive (n=18,649) 81.5 (78.9, 84.3) 423.4 (412.5, 434.6) 330.5 (321.8, 339.4) 
   Managed care plan (n=332,193) 109.5 (108.8, 110.3) 458.8 (456.1, 461.5) 364.6 (362.4, 366.8) 
   High deductible plan (n=244,662) 105.5 (104.6, 106.3) 575.2 (571.5, 579.0) 454.0 (451.0, 457.0) 
  Missing (n= 51,728)       
Received primary care in the past 
year 
      
   No (n=1,493,373) 98.4 (98.1, 98.8) 472.6 (471.4, 473.9) 368.0 (366.9, 369.0) 
   Yes (n=197,850) 119.8 (118.7, 120.9) 676.3 (671.4, 681.2) 533.9 (530.0, 537.9) 
Abbreviations: IR=incidence rate; CI=confidence interval; HPV=human papillomavirus vaccine; Tdap=tetanus-diphtheria-acellular pertussis 






Table 4.4. Incidence rate ratios for the association of urbanicity with HPV, Tdap, and MenACWY vaccination among adolescents, 
stratified by region, 2009-2014 
  HPV                                          
IRR (95% CI) 
Tdap                                     
IRR (95% CI) 
Men                                     
IRR (95% CI) 
All Regions (n=1,655,781)* Urban 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  Rural 0.76 (0.75, 0.77) 0.58 (0.57, 0.58) 0.53 (0.53, 0.54) 
Northeast (n=247,991) Urban 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  Rural 1.09 (1.05, 1.13) 0.86 (0.84, 0.88) 0.79 (0.77, 0.82) 
North Central (n=426,605) Urban 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  Rural 0.76 (0.74, 0.77) 0.50 (0.49, 0.50) 0.46 (0.46, 0.47) 
South (n=637,009) Urban 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  Rural 0.77 (0.75, 0.78) 0.60 (0.59, 0.60) 0.55 (0.54, 0.56) 
West (n=343,161) Urban 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  Rural 0.68 (0.66, 0.71) 0.55 (0.54, 0.57) 0.46 (0.45, 0.47) 
Abbreviations: IRR=incidence rate ratio; CI=confidence interval; MSA=metropolitan statistical area; HPV=human papillomavirus vaccine; 
Tdap=tetanus-diphtheria-acellular pertussis vaccine; MenACWY=meningococcal conjugate vaccine. 







Figure 4.1. Combinations of vaccinations received among adolescents who received any vaccination during follow-up. The 







Figure 4.2. Incidence rates per 10,000 person-months of receiving Tdap+MenACWY vaccination in the same visit, and 
HPV+Tdap+MenACWY vaccination in the same visit. Incidence rates are stratified by birth year to demonstrate cohort effects on co-








Figure 4.3. Cumulative incidence curves for HPV vaccination within the ACIP-recommended age range, showing differences in 





Table 5.1. Incidence of adolescent vaccination and complex regional pain syndrome among adolescent girls, 2006-2014 
(N=1,232,572) 
Median duration of follow-up (IQR), years 1.66 (0.67, 3.25) 
  
Cumulative incidence (incidence proportion) of adolescent vaccination 
   HPV vaccination 286,965 (23.3%) 
   Tdap vaccination 621,342 (50.4%) 
   MenACWY vaccination 542,105 (44.0%) 
   Tdap+MenACWY vaccination 437,414 (35.5%) 
   HPV+Tdap+MenACWY vaccination 219,238 (17.8%)   
Cumulative incidence (incidence proportion) of CRPS* 563 (0.045%) 
Cumulative incidence (incidence proportion) of possible CRPS † 1,689 (0.14%) 
  
Incidence rate (95% CI) of CRPS per 100,000 person-years 20.57 (18.94, 22.34) 
Abbreviations: IQR=interquartile range; HPV=human papillomavirus vaccine; Tdap=tetanus-diphtheria-acellular pertussis vaccine; 
MenACWY=meningococcal conjugate vaccine; 4vHPV=quadrivalent HPV vaccine; 2vHPV=bivalent HPV vaccine; CRPS=complex regional 
pain syndrome; CI=confidence interval. 
*CRPS cases include diagnoses of reflex sympathetic dystrophy and algoneurodystrophy.  






Table 5.2. Relative hazard of CRPS among adolescent girls within 30 and 90 days following adolescent vaccination, 2006-2014 
(N=1,232,572) 
 Within 30 days of vaccination Within 90 days of vaccination 
 Crude HR (95% CI) 
Adjusted HR* (95% 
CI) Crude HR (95% CI) 
Adjusted HR* (95% 
CI) 
HPV vaccination      
     No 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
     Yes 1.48 (0.87, 2.51) 1.41 (0.83, 2.40) 1.51 (1.09, 2.09) 1.39 (1.00, 1.93)                            
Tdap vaccination      
     No 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
     Yes 0.86 (0.43, 1.73) 1.29 (0.64, 2.59) 1.00 (0.67, 1.47)  1.43 (0.97, 2.11)  
MenACWY vaccination      
     No 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
     Yes 0.86 (0.41, 1.81)  1.21 (0.57, 2.55)                            1.14 (0.77, 1.68) 1.54 (1.05, 2.28) 
Tdap+MenACWY 
vaccination      
     No 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
     Yes 0.76 (0.31, 1.83) 1.21 (0.50, 2,93) 1.10 (0.71, 1.70) 1.67 (1.08, 2.60) 
Abbreviations: HPV=human papillomavirus vaccine; Tdap=tetanus-diphtheria-acellular pertussis vaccine; MenACWY=meningococcal conjugate vaccine; 
CRPS=complex regional pain syndrome; HR=hazard ratio; CI=confidence interval. 






Table 5.3. Relative hazard of CRPS among adolescent girls at any time following adolescent vaccination, 2006-2014 (N=1,232,572) 
 Crude HR (95% CI) Adjusted HR
* (95% CI) 
Ever received HPV vaccination    
     No 1.0 (ref) 1.0 (ref) 
     Yes 1.19 (0.98, 1.46) 0.81 (0.66, 0.99) 
Ever received Tdap vaccination   
     No 1.0 (ref) 1.0 (ref) 
     Yes 1.59 (1.34, 1.89) 1.09 (0.91, 1.29) 
Ever received MenACWY vaccination   
     No 1.0 (ref) 1.0 (ref) 
     Yes 1.70 (1.43, 2.02) 1.19 (1.00, 1.42) 
Ever received concomitant Tdap+MenACWY 
vaccination   
     No 1.0 (ref) 1.0 (ref) 
     Yes 1.56 (1.31, 1.85) 1.27 (1.06, 1.51) 
Abbreviations: HPV=human papillomavirus vaccine; Tdap=tetanus-diphtheria-acellular pertussis vaccine; MenACWY=meningococcal conjugate vaccine; 
CRPS=complex regional pain syndrome; HR=hazard ratio; CI=confidence interval. 






Table 5.4. Relative hazard of CRPS among adolescent girls following concomitant adolescent vaccination in the past 30 or 90 days, 
2006-2014 (N=1,232,572) 
   
 Vaccinated in past 30 days Vaccinated in past 90 days 
 Adjusted HR (95% CI)







1.62 (0.85, 3.06) HPV + Tdap/MenACWY/Influenza*   2.30 (0.80, 6.56) 
     




✝  4.15 (0.69, 24.84) 1.35 (0.52, 3.51) 
Abbreviations: HPV=human papillomavirus vaccine; Tdap=tetanus-diphtheria-acellular pertussis vaccine; MenACWY=meningococcal conjugate vaccine; 
CRPS=complex regional pain syndrome; HR=hazard ratio; CI=confidence interval. 
*Model includes an interaction term representing receipt of HPV vaccination and receipt of Tdap, MenACWY, or influenza vaccination. 
✝Model includes an interaction term representing receipt of concomitant Tdap+MenACWY vaccination and receipt of HPV vaccination. 








APPENDIX 1: DIAGNOSES AND PROCEDURES FOR PHYSICAL TRAUMA 
Appendix 1. Diagnoses and procedures for physical trauma 
Diagnosis Description ICD-9 Codes 
Fracture Pelvis 808, 808.x, 808.xx 
 Trunk 809, 809.x  
 
Upper body: Trunk, shoulder, arm, wrist, hand, 
finger 810.x-819.x 
 Lower body: Thigh, leg, knee, ankle, toe 820.x-828x 
 Unspecified bones 829, 829.x 
Dislocation Upper body: Shoulder, elbow, wrist, finger 831.x-834.x 
 Lower body: Hip, knee, ankle, foot 835.x-838.x 
 Other, multiple dislocations 839, 839.x, 839.xx 
Sprain, strain Upper body: Shoulder, arm, elbow, wrist, hand 840.x-842.x 
 Lower body: hip, thigh, leg, knee, ankle, foot 843.x-846.x 
 Other, unspecified parts of back 847, 847.x 
 Other ill-defined 848, 848.x 
Road vehicle accidents Traffic accident 
E81, E81.x, 
E81.xx 






Surgeries, treatment of 
fractures and dislocations 
Upper body: Shoulder, elbow, arm, wrist, hand, 
finger 23000-26989 
 Lower body: Pelvis, thigh, leg, knee, ankle, foot, toe 26990-28899 
 
Extracranial nerves, peripheral nerves, autonomic 
nervous system 64400-64999 
Casting, splinting, 
strapping 
Upper body: Body, shoulder, arm, wrist, hand, 
finger 29000-29280 
 Lower body: Hip, leg, knee, foot 29305-29590 
 Cast: Removal, revision 29700-29799 
Medical equipment Immobilization devices 
L21x-L39x, L43x, 
L46x 





 Cast, splint supplies Q4001-Q4051 
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APPENDIX 2: DIAGNOSES, PROCEDURES, AND PRESCRIPTION DRUGS FOR 
MENTAL ILLNESS 
Appendix 2. Diagnoses, procedures, and prescription drugs for mental illness 
Diagnosis   ICD-9 Codes 
Transient mental disorders 293, 293.x, 293.xx 
Schizophrenic disorders 295, 295.x, 295.xx 
Episodic mood disorders 296, 296.x, 296.xx 
Delusional disorders 297, 297.x 
Non-organic psychoses 298, 298.x 
Anxiety, dissociative, and somatoform disorders 300, 300.x, 300.xx,  
Personality disorders 301, 301.x, 301.xx 
Physiological malfunction arising from mental 
factors 306, 306.x, 306.xx 
Special syndromes or symptoms, not elsewhere 
classified (including sleep disorders, eating 
disorders, pain disorders) 307, 307.x, 307.xx 
Acute reactions to stress 308, 308.x,  
Adjustment disorders 309, 309.x,  309.xx 
Non-psychotic mental disorders 310, 310.x, 310.xx 
Depressive disorder, not elsewhere classified 311 
Conduct disorders 312, 312.x, 312.xx 
Emotional disturbance  313, 313.x, 313.xx 
Hyperkinetic disorders 314,  314.x, 314.xx 
Procedure CPT Codes 
Psychotherapy, psychiatric diagnostic 
examination 
908xx, G007x, G008x, G0090-G0094, 4060f, 
4062f, G0410, G0411 
Prescription Generic Drug Name 
Anti-anxiety drugs Alprazolam, buspirone, hydroxizine, lorazepam 
Antidepressant drugs 
Amitriptyline, bupropion, citalopram, 
clomipramine, desipramine, doxepin, duloxetine, 
escitalopram, fluoxetine, imipramine, mirtazapine, 
nortriptyline, paroxetine, phenelzine, sertraline, 
tranylcypromine, trazodone,  venlafaxine 
Antipsychotic drugs 
Aripiprazole, chlorpromazine, clozapine, 
fluphenazine, haloperidol, lithium, olanzapine, 
paliperiodone, perphenazine, prochlorperazine, 
quetiapine, risperidone, thiothixine, 
trifluoperazine, ziprasidone 
Sleep aids 
Chloral hydrate, estazolam, eszopiclone, 
ramelteon, temazepam, zaleplon, zolpidem 
Hyperactivity, narcolepsy drugs 
Amphetamine salt combination, atomoxetine, 
dexmethylphenidate, dextroamphetamine, 
lisdexamfetamine, methylphenidate, modafinil 
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